Puma Biotechnology, Inc. (PBYI)
10.52
+0.32
(+3.14%)
USD |
NASDAQ |
Oct 15, 16:00
10.52
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Cash from Operations (TTM) : 41.15M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 41.15M |
| March 31, 2026 | 53.61M |
| December 31, 2025 | 41.80M |
| September 30, 2025 | 42.99M |
| June 30, 2025 | 44.34M |
| March 31, 2025 | 31.28M |
| December 31, 2024 | 38.92M |
| September 30, 2024 | 33.77M |
| June 30, 2024 | 33.34M |
| March 31, 2024 | 35.61M |
| December 31, 2023 | 27.01M |
| September 30, 2023 | 24.24M |
| June 30, 2023 | 30.88M |
| March 31, 2023 | 13.71M |
| December 31, 2022 | -15.83M |
| September 30, 2022 | -28.94M |
| June 30, 2022 | -35.71M |
| March 31, 2022 | -21.91M |
| December 31, 2021 | 20.65M |
| September 30, 2021 | 20.45M |
| June 30, 2021 | 11.67M |
| March 31, 2021 | 27.97M |
| December 31, 2020 | 0.773M |
| September 30, 2020 | 7.974M |
| June 30, 2020 | -1.053M |
| Date | Value |
|---|---|
| March 31, 2020 | 26.97M |
| December 31, 2019 | 22.38M |
| September 30, 2019 | 27.86M |
| June 30, 2019 | 27.90M |
| March 31, 2019 | -33.98M |
| December 31, 2018 | -24.10M |
| September 30, 2018 | -66.76M |
| June 30, 2018 | -114.41M |
| March 31, 2018 | -142.68M |
| December 31, 2017 | -172.47M |
| September 30, 2017 | -177.82M |
| June 30, 2017 | -157.81M |
| March 31, 2017 | -142.70M |
| December 31, 2016 | -141.69M |
| September 30, 2016 | -133.76M |
| June 30, 2016 | -135.74M |
| March 31, 2016 | -139.47M |
| December 31, 2015 | -154.47M |
| September 30, 2015 | -139.90M |
| June 30, 2015 | -127.35M |
| March 31, 2015 | -110.18M |
| December 31, 2014 | -77.20M |
| September 30, 2014 | -72.32M |
| June 30, 2014 | -60.01M |
| March 31, 2014 | -53.61M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Anika Therapeutics, Inc. | 5.977M |
| Arcutis Biotherapeutics, Inc. | 39.31M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Savara, Inc. | -110.38M |